Istituto Clinico Humanitas
Rozzano, Milano, 20089, Italy
NCT Number: NCT03578939
All patients referring to the U.O .of Digestive Endoscopy of the Humanitas Hospital to undergo EUS with biopsy in the pre-treatment evaluation of locally advanced pancreatic adenocarcinoma, satisfying all the inclusion criteria and without any of the exclusion criteria, will be enrolled.
Patients will then undergo endoscopic procedures (EUS with biopsy) provided by good clinical practice in consideration of the suspected diagnosis for which they come to Investigator's attention.
Biopsy will be performed using a histology needle (22 G, Acquire, Boston Scientific, MA, United States). The obtained material will be processed in the Pathological Anatomy. A small part of this will be sent to the NGS analysis.
At the time of preparation for the examination, the patients will be asked for blood collection (10 ml of blood) in order to evaluate any circulating tumor cells that will be identified by SmartBioSurface technique (Tethis S.p.A) and analyzed by appropriate molecular markers and NGS.
The clinical evaluation of the patient will take place at 6 months from the date of the procedure, through telephone contact and / or outpatient visit.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Rozzano, Milano, 20089, Italy
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
NGS Sequencing on Biopsy samples
Time frame: 18 Months
Time frame: 18 Months
Istituto Clinico Humanitas
Other
Next Generation Sequencing di Cellule Tumorali Nell'Adenocarcinoma Pancreatico Localmente Avanzato
Acronym: LAPC-NGS-A/001
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02905578
Adenocarcinoma, Cancer of Pancreas
Iowa City, Iowa, United States
View Trial DetailsNCT00911118
Adenocarcinoma, Carcinoma
Commack, New York, United States
View Trial DetailsNCT03415854
Adenocarcinoma, Carcinoma
Scottsdale, Arizona, United States
View Trial DetailsNCT02664935
Adenocarcinoma, Bronchial Neoplasms
Aberdeen, United Kingdom
View Trial Details